Evidence map›Paper›PMID 40411530›Full record

ReviewCurrent atherosclerosis reports2025

Biomarkers Differentiating Plaque Erosion from Stable Plaque.

Teruo Sekimoto, Tatsuya Shiraki, Rika Kawakami, Atsushi Sakamoto, Takamasa Tanaka, Tomoyo Hamana, Aloke V Finn, Renu Virmani

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in Current atherosclerosis reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Teruo SekimotoCVPath Institute, Inc, 19 Firstfield Road, Gaithersburg, MD, USA.
Tatsuya ShirakiCVPath Institute, Inc, 19 Firstfield Road, Gaithersburg, MD, USA.
Rika KawakamiCVPath Institute, Inc, 19 Firstfield Road, Gaithersburg, MD, USA.
Atsushi SakamotoCVPath Institute, Inc, 19 Firstfield Road, Gaithersburg, MD, USA.
Takamasa TanakaCVPath Institute, Inc, 19 Firstfield Road, Gaithersburg, MD, USA.
Tomoyo HamanaCVPath Institute, Inc, 19 Firstfield Road, Gaithersburg, MD, USA.
Aloke V FinnCVPath Institute, Inc, 19 Firstfield Road, Gaithersburg, MD, USA.
Renu VirmaniCVPath Institute, Inc, 19 Firstfield Road, Gaithersburg, MD, USA. rvirmani@cvpath.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewPlaque erosion is the second most frequent cause of acute coronary syndrome, yet the biological processes and biomarkers associated with erosion remain incompletely understood. This review aims to examine the current understanding of plaque erosion, with a focus on identifying potential biomarkers. RECENT

findingsRecent studies have identified distinct pathophysiological characteristics associated with plaque erosion, including variations in inflammatory response and immune cell infiltration within the culprit lesions and thrombi. Additionally, differences in the expression patterns of specific molecules have been noted, suggesting unique underlying mechanisms that contribute to plaque erosion. Understanding the differential expression and role of immune cells and biomarkers in erosion may be crucial for developing targeted therapies. The identification of biomarkers may help in the early detection and treatment of erosion-prone plaques, potentially reducing the incidence of acute coronary events.

Indexed as

Acute Coronary SyndromeBiomarkersCoronary Artery DiseasePlaque, AtheroscleroticDiagnosis, DifferentialHumansBiomarkersAcute myocardial infarctionBiomarkersCoronary artery diseasePlaque erosion

Identifiers

PMID40411530

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.